Description
CEFITYN-CV325
Cefixime 200 mg + Clavulanic Acid 125 mg Tablets
Powerful Dual-Action Antibiotic Therapy for Effective Infection Management
CEFITYN-CV325 combines the proven efficacy of Cefixime 200 mg with the beta-lactamase inhibitor Clavulanic Acid 125 mg, offering enhanced protection against a broad range of bacterial infections, including those caused by beta-lactamase-producing organisms.
Key Features
Broad-spectrum antibacterial coverage
Effective against resistant bacterial strains
Dual-action formula for improved therapeutic outcomes
Convenient oral dosage for better patient compliance
Manufactured under stringent quality standards
Composition
Cefixime IP – 200 mg
Clavulanic Acid (as Potassium Clavulanate Diluted) – Equivalent to 125 mg
Indications
CEFITYN-CV325 may be prescribed by qualified healthcare professionals for the treatment of susceptible bacterial infections, including:
Respiratory tract infections
Ear, nose, and throat (ENT) infections
Urinary tract infections (UTIs)
Skin and soft tissue infections
Other bacterial infections as clinically indicated
Note: Use only under the advice of a registered medical practitioner. Antibiotics should be taken exactly as prescribed to help reduce antimicrobial resistance.
Marketed by MEDROOTS BIOPHARMA
MEDROOTS BIOPHARMA is a growing pharmaceutical company offering quality, innovative, and affordable healthcare products across India. The company provides PCD Pharma Franchise and monopoly business opportunities, backed by a diverse product portfolio and a commitment to quality and customer satisfaction.
For more information, visit: Medroots Biopharma
